The primary objective of this study is to determine in subjects with metastatic measurable
bladder cancer (or urothelial cancers originating elsewhere in the genitourinary tract) who
have progressed on 1 prior chemotherapeutic regimen the objective response rate to treatment
with amrubicin. The secondary objectives will be to evaluate progression-free survival,
survival at 1 year, and the safety of amrubicin as second-line therapy in patients with
metastatic urothelial carcinoma.